CoChat

P53 and its molecular basis to chemoresistance in breast cancer

Knappskog, Stian, Lønning, Per Eystein · 2012 · Expert Opinion on Therapeutic Targets
Cited by 74

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: TP53 mutations have been associated with resistance to anthracyclines and mitomycin in breast cancer. This review examines the potential roles of different components in the p53 cascade with respect to drug resistance. AREAS COVERED: Literature was searched using the ISI Web and Pubmed. Considering p53 activation in response to genotoxic stress and phosphorylations by ataxia telangiectasia mutated/ataxia telangiectasia and radiation resistance gene 3 related (ATM/ATR). Downstream checkpoint proteins chk1 and chk2 are also considered to be of major importance. Recently, nonsense mutations in CHEK2, encoding the chk2 protein, were found to predict resistance to anthracycline therapy in some tumours harbouring wild-type TP53. While mouse double minute (MDM)2 or MDMX protein overexpression (often due to gene amplifications) may inactivate p53 in different tumour forms, so far, there is no evidence for MDM2 amplifications in breast cancers resistant to anthracyclines. The roles of p53 isoforms and p53-induced transcription of non-coding RNA remain to be defined. EXPERT OPINION: Disturbances affecting the 'p53 pathway(s)' may play a key role in chemoresistance in cancer. Although TP53 is not a clinical marker for drug resistance, like other genes (such as breast cancer associated 1/2 (BRCA1/2)) it may be considered a 'beacon' identifying critical gene cascades.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728222.2011.640322

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 74

Metadata

Authors
Knappskog, S., & Lønning, P. E.
Venue
Expert Opinion on Therapeutic Targets
Published
2012-02-08
Volume
16
Issue
sup1
Pages
S23-S30
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2170204650
Cited by
74
References
13
FWCI
3.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: P53 and its molecular basis to chemoresistance in breast cancer. https://app.cochat.ai/papers/10.1517/14728222.2011.640322
The paper
Knappskog, S., & Lønning, P. E. (2012). P53 and its molecular basis to chemoresistance in breast cancer. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2011.640322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.